Original ArticlePrimary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
Under a Creative Commons license
open access
Key words
advanced breast cancer
atezolizumab
immune checkpoint inhibitor
PD-L1
paclitaxel
triple-negative breast cancer
Cited by (0)
© 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.